The company states: "MediciNov announced that Health Canada has completed its review of the clinical trial application and has granted authorization to commence a grant-funded, multi-center, randomized, clinical trial to evaluate MN-166, or ibudilast, and other therapies for the treatment of Long COVID, the lingering symptoms of COVID-19. The trial, entitled REcovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine, or "RECLAIM," is a collaboration between MediciNova and the University Health Network, the largest hospital-based research program in Canada. MediciNova will supply the study drug and will provide regulatory and safety follow-up support."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MNOV:
- MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
- MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
- MediciNova completes enrollment in Phase 2b clinical trial of MN-166
- MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
- MediciNova completes enrollment in Phase 2 trial of MN-166 in glioblastoma